NewswireTODAY - /newswire/ - Mumbai, Maharashtra, India, 2007/01/15 - IBS Centre for Bioinformatics to offer state-of-the-art research-based Biotechnology solutions towards modern medicine and therapy research.

Intelligent Business Systems (IBS) and Government of Gujarat have signed a Memorandum of Understanding (MoU) today to partner in Gujarat State Biotechnology Mission. Gujarat is the first state in India to set up a Biotechnology Solutions Venture which will be aimed at Research Outsourcing. As part of the MoU, Intelligent Business Systems Centre for Bioinformatics (CfB) along with Shanku’s Group will be providing the Bioinformatics & Biotechnology research based solutions respectively.

IBS will deal with computer-aided drug discovery, drug interaction and bio-analysis. Also, Shanku’s group will be investing Rs. 40 crore for the venture.

Speaking on the occasion, Dr. Kaustubh Chokshi, CEO and co-Founder, IBS, said, “Gujarat with its very strong Pharma, Healthcare and Agriculture sectors offers an ideal platform to venture into the emerging Biotechnology industry. IBS with its strong academic roots and research based approach to providing innovative solutions, is privileged to be part of this initiative to tap the growing opportunity that Biotechnology offers.”

He added, “At IBS we pioneer the use of novel and developmental bioinformatics research. IBS (intelligentsystems.biz) will offer cutting edge solutions to facilitate the goals of modern medicine and therapy research.”

Intelligent Business Systems’ CfB specialises in research and data analysis, which can be extended to provide an invaluable analytical insight into biological data and utilities to aid the scientific and commercial community in the understanding of genomic and proteomic data.

CfB will collaborate with academia on problems of relevance to improve medication and healthcare delivery. The mathematical approach has numerous cutting-edge applications in modern medicine and therapy development.
These include:

• Individuals responding adversely to one or more drugs;
• Predicting disease and treatment outcomes;
• Improved economic and practical efficiencies in healthcare delivery, thus better targeting high cost treatment to those patients most likely to benefit from it;
• Computationally complete genome sequence analysis and comparative genomics;
• Development of intelligent systems for genome;
• Protein interaction maps using gene fusion events;
• Pattern discovery;
• Evolution of the transcriptional machinery;
• Development of standards for genome sequence annotation;
• Document clustering and information extraction from biological text;
• Precocious diagnosis of life-threatening disease.

Agency / Source: Adfactors PR (P) Ltd

Availability: All Regions (Including Int'l)

Traffic Booster: [/] Quick NewswireToday Visibility Checker

Distribution / Indexing: [+]